The new exocrine pancreas staging system by the American Joint Committee for Cancer (AJCC, Eighth edition) for pancreatic ductal adenocarcinoma (PDAC) is entirely size-based. Tumors are classified as pT1, ≤2 cm (pT1a, ≤0.5 cm; pT1b, >0.5 cm and <1 cm; pT1c, 1-2 cm), pT2, >2 cm and ≤4 cm, and pT3, >4 cm. The previous stage T3, tumor extension beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery, does not exist anymore. There is no change in stage T4. Design: We retrospectively analyzed 79 cases of pancreatic ductal adenocarcinoma (with or without neoadjuvant therapy) from 2010 through 2017 and restaged them based on the new AJCC, Eighth edition, system. Results: We retrospectively analyzed 79 cases (44 women and 35 men; mean age of 65 years). Twenty-four cases were post neoadjuvant treatment. Reclassifying the cases by AJCC, Eighth edition, resulted in restaging of 57 cases (72%): 45 of the cases (57%) were downstaged, six cases (7.6%) were upstaged, and there was no change in the staging of 28 cases (35.5%). A total of seven patients were upstaged from T2 to T3, two of whom are deceased at the time of this study. A total of 45 cases were downstaged. The majority (39 cases, 86.6%) was downstaged from T3 to T2, 18 (40%) of whom were deceased at the time of the study. Conclusions: Our study shows how AJCC, Eighth edition, affects the staging in pancreatic ductal carcinomas. Largescale clinical studies are needed to validate the new system and correlate it with patient outcomes.
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Fundic Gland Polyp Biopsies: A Cost-Effectiveness Analysis at One Academic Center
Elizabeth Kertowidjojo, MD, PhD, Sui Zee, MD, FASCP; Stony Brook University Hospital, Stony Brook, NY Fundic gland polyps (FGPs) are the most common gastric polyp in the US, found in up to 5.9% of all adults undergoing esophagogastroduodenoscopy (EGD). They are usually incidental findings and considered to be a benign entity with virtually no malignant potential.
When found during EGD, the current practice is to obtain a biopsy. In 2010, almost 3 million EGDs were performed in the US, leading to over 28,000 FGP biopsies and an estimated cost of almost $7 million. This number will grow, as the number of EGDs rises. The diagnosis of FGP does not require further intervention or surveillance. Dysplasia in sporadic FGP is rare, and its clinical implication is uncertain. We hypothesize that the practice of routine FGP biopsy is unnecessary, and its elimination will reduce cost without compromising patient care. We performed a search of our pathology database for cases of FGPs diagnosed from endoscopic biopsies at Stony Brook University Hospital (SBUH) from 2010 to 2015. Data was also collected regarding the presence of dysplasia, and the patient's gender, age, and race. We found that from 2010 to 2015, the number of FGP cases diagnosed at SBUH has increased by 48%. The estimated annual cost rose by almost $15,000. Only four cases of dysplasia were identified, constituting 0.5% of all diagnosed FGPs. We conclude that the increasing rate of FGP diagnosis predicts a continuing trend of rising costs. Given the benign nature of this entity, the cost does not translate to an altered treatment course or improved patient outcome. Predicting typical FGPs based on endoscopic features has been shown to be reliable, making a histological diagnosis unnecessary. Ultimately, the practice of routine FGP biopsy is one based more on defensive medicine rather than clinical impact and can be eliminated to reduce costs without compromising patient care. 
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